Creating a new treatment using exosomes from organoids for osteoarthritis
Development of an Organoid-Derived Exosome Product for the Treatment of Osteoarthritis
This study is exploring a new treatment for osteoarthritis using tiny particles called exosomes from special lab-grown tissues, which might help reduce inflammation and repair cartilage, aiming to find the best way to make these particles work for people with this painful condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10888061 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for osteoarthritis (OA) by utilizing exosomes derived from multi-tissue organoids. These exosomes are believed to have immunoregulatory properties that can help reduce inflammation and promote cartilage repair. The study aims to identify the optimal stage of organoid development to maximize the therapeutic effects of these exosomes. By targeting the underlying inflammation associated with OA, this approach seeks to provide a more effective treatment option for patients suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with osteoarthritis, particularly those experiencing significant joint pain and inflammation.
Not a fit: Patients with osteoarthritis who are not experiencing inflammation or those with advanced joint degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking therapy that not only alleviates symptoms of osteoarthritis but also slows its progression.
How similar studies have performed: While the use of exosomes in treating osteoarthritis is a relatively novel approach, preliminary studies have shown promise in similar applications, indicating potential for success.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Ramachandran, Sabarinathan — University of Minnesota
- Study coordinator: Ramachandran, Sabarinathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.